骨科

订阅

MedSci主页 / 所有栏目 / 骨科

Bone：雷帕霉素通过对骨生成和血管生成的积极作用，通过铁积累改善高周转性骨质疏松症中的骨量

2019-01-08 MedSci MedSci原创

关注

铁积累是I型骨质疏松症的独立危险因素，但该现象的分子机制尚未明确定义，尚未见有效治疗。 在这里，我们发现mTOR水平在具有铁积累的野生型小鼠模型和具有铁积累的高周转性骨质疏松症的转基因小鼠模型（Hepc-/-）中均增加。我们表明，增加的mTOR水平可以抑制骨和体外Cxcl9的成骨和血管生成。通过雷帕霉素在小鼠模型中抑制mTOR并且通过siRNA转染在体外抑制mTOR恢复了骨生成和血管生成。 这些发

铁积累是I型骨质疏松症的独立危险因素，但该现象的分子机制尚未明确定义，尚未见有效治疗。

在这里，我们发现mTOR水平在具有铁积累的野生型小鼠模型和具有铁积累的高周转性骨质疏松症的转基因小鼠模型（Hepc-/-）中均增加。我们表明，增加的mTOR水平可以抑制骨和体外Cxcl9的成骨和血管生成。通过雷帕霉素在小鼠模型中抑制mTOR并且通过siRNA转染在体外抑制mTOR恢复了骨生成和血管生成。

这些发现揭示了mTOR在具有铁积累的高周转性骨质疏松症中的成骨和血管生成中的作用，并且表明雷帕霉素靶向mTOR改善了骨生成和血管生成以改善骨量。

原始出处：

Wu J, Wang A, et al., Rapamycin improves bone mass in high-turnover osteoporosis with iron accumulation through positive effects on osteogenesis and angiogenesis. Bone. 2019 Jan 2. pii: S8756-3282(18)30469-1. doi: 10.1016/j.bone.2018.12.019.

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915198, encodeId=ca84191519809, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Apr 22 11:08:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667178, encodeId=6634166e17898, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 23 16:08:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592527, encodeId=672d159252ea3, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Wed Jan 09 17:08:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
    2019-04-22 apoenzyme

    #Bone#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1915198, encodeId=ca84191519809, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Apr 22 11:08:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667178, encodeId=6634166e17898, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 23 16:08:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592527, encodeId=672d159252ea3, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Wed Jan 09 17:08:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
    2019-08-23 clmlylxy

    #骨量#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1915198, encodeId=ca84191519809, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Apr 22 11:08:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667178, encodeId=6634166e17898, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 23 16:08:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592527, encodeId=672d159252ea3, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Wed Jan 09 17:08:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
    2019-01-09 Eleven17

    #骨质#

    0